{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluvoxamine", "query": { "intervention": "Fluvoxamine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluvoxamine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-01T21:37:40.374Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00456560", "title": "AV650 Drug-Drug Interaction Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "AV650", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avigen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2007-04", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2007-09-17", "last_synced_at": "2026-09-01T21:37:40.374Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00456560" }, { "nct_id": "NCT02893371", "title": "Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Lithium Carbonate", "type": "DRUG" }, { "name": "Lamotrigine", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" }, { "name": "Oxcarbazepine", "type": "DRUG" }, { "name": "Carbamazepine", "type": "DRUG" }, { "name": "Ziprasidone", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Fluoxetine / Olanzapine", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Perphenazine", "type": "DRUG" }, { "name": "Clozapine", "type": "DRUG" }, { "name": "Asenapine", "type": "DRUG" }, { "name": "Lurasidone", "type": "DRUG" }, { "name": "Paliperidone", "type": "DRUG" }, { "name": "Mirtazapine", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Desvenlafaxine", "type": "DRUG" }, { "name": "Duloxetine", "type": "DRUG" }, { "name": "Venlafaxine", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" }, { "name": "Escitalopram", "type": "DRUG" }, { "name": "Fluoxetine", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" }, { "name": "Sertraline", "type": "DRUG" }, { "name": "Vilazodone", "type": "DRUG" }, { "name": "Doxepin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1037352, "start_date": "2016-09", "completion_date": "2019-06-30", "has_results": false, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-09-01T21:37:40.374Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02893371" }, { "nct_id": "NCT03511118", "title": "Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lactating Women on Select DOI", "Breastfed Infants of Mothers on Select DOI" ], "interventions": [ { "name": "Tranexamic acid (TXA)", "type": "DRUG" }, { "name": "labetalol", "type": "DRUG" }, { "name": "metformin", "type": "DRUG" }, { "name": "nifedipine", "type": "DRUG" }, { "name": "clindamycin", "type": "DRUG" }, { "name": "oxycodone", "type": "DRUG" }, { "name": "azithromycin", "type": "DRUG" }, { "name": "escitalopram", "type": "DRUG" }, { "name": "sertraline", "type": "DRUG" }, { "name": "ondansetron", "type": "DRUG" }, { "name": "Ciprofloxacin", "type": "DRUG" }, { "name": "Doxycycline", "type": "DRUG" }, { "name": "Levofloxacin", "type": "DRUG" }, { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Sumatriptan", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" }, { "name": "Cyclobenzaprine", "type": "DRUG" }, { "name": "Furosemide", "type": "DRUG" }, { "name": "Gabapentin", "type": "DRUG" }, { "name": "Hydrochlorothiazide", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Topiramate", "type": "DRUG" }, { "name": "Trazodone", "type": "DRUG" }, { "name": "Valganciclovir", "type": "DRUG" }, { "name": "Venlafaxine", "type": "DRUG" }, { "name": "Verapamil", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Amoxicillin", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Duloxetine", "type": "DRUG" }, { "name": "Hydrocodone", "type": "DRUG" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" }, { "name": "Buprenorphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1600, "start_date": "2018-10-04", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-01T21:37:40.374Z", "location_count": 20, "location_summary": "La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03511118" }, { "nct_id": "NCT04342663", "title": "A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID 19", "Coronavirus" ], "interventions": [ { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2020-04-10", "completion_date": "2020-12-12", "has_results": true, "last_update_posted_date": "2021-07-09", "last_synced_at": "2026-09-01T21:37:40.374Z", "location_count": 2, "location_summary": "Belleville, Illinois • St Louis, Missouri", "locations": [ { "city": "Belleville", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04342663" }, { "nct_id": "NCT05888207", "title": "A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Male Subjects" ], "interventions": [ { "name": "Savolitinib", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 16, "start_date": "2023-06-02", "completion_date": "2023-08-17", "has_results": false, "last_update_posted_date": "2023-08-29", "last_synced_at": "2026-09-01T21:37:40.374Z", "location_count": 1, "location_summary": "Brooklyn, Maryland", "locations": [ { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05888207" }, { "nct_id": "NCT03534063", "title": "Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pain, Postoperative" ], "interventions": [ { "name": "CYP2D6-guided opioid therapy", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 260, "start_date": "2018-06-07", "completion_date": "2020-04-29", "has_results": true, "last_update_posted_date": "2023-07-17", "last_synced_at": "2026-09-01T21:37:40.374Z", "location_count": 3, "location_summary": "Gainesville, Florida • Summerfield, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Summerfield", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03534063" }, { "nct_id": "NCT03930602", "title": "Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "BMS-986165", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 16, "start_date": "2019-05-01", "completion_date": "2019-05-27", "has_results": false, "last_update_posted_date": "2021-11-17", "last_synced_at": "2026-09-01T21:37:40.374Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03930602" }, { "nct_id": "NCT03321526", "title": "A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "JNJ-42847922", "type": "DRUG" }, { "name": "Placebo Matching to JNJ-42847922", "type": "DRUG" }, { "name": "Quetiapine XR", "type": "DRUG" }, { "name": "Placebo Matching to Quetiapine XR", "type": "DRUG" }, { "name": "Selective Serotonin Reuptake Inhibitor (SSRI)", "type": "DRUG" }, { "name": "Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 107, "start_date": "2017-12-12", "completion_date": "2019-06-27", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-09-01T21:37:40.374Z", "location_count": 50, "location_summary": "Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Garden Grove", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03321526" }, { "nct_id": "NCT06969287", "title": "Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Delirium", "Surgery-Complications" ], "interventions": [ { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 46, "start_date": "2026-04-06", "completion_date": "2028-04-01", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-01T21:37:40.374Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06969287" }, { "nct_id": "NCT05894564", "title": "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Susanna Naggie, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 1208, "start_date": "2022-08-25", "completion_date": "2023-05-30", "has_results": true, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-09-01T21:37:40.374Z", "location_count": 103, "location_summary": "Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 90 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "North Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05894564" } ] }